Guidelines for ATC classification and DDD assignment - WHOCC

The DDD for the combination of levodopa and decarboxylase
inhibitor is based on the content of levodopa, see ATC index.
N04BB Adamantane derivatives
N04BC Dopamine agonists
Bromocriptine used in parkinsonism is classified in this group (e.g.
tablets of 5 mg and 10 mg). Low strength bromocriptine tablets (e.g.
2.5 mg) used as a prolactine inhibitor are classified in G02CB -
Prolactine inhibitors.
Cabergoline used in parkinsonism is classified in this group (e.g. tablets
of 1 mg). Low strength cabergoline tablets (0.5 mg) used as a
prolactine inhibitor are classified in G02CB.
Lisuride in high strength formulations (e.g. 0.2 mg tablets), which is also
used in the treatment of Parkinsonism, are classified in G02CB while
lisuride in low strength formulations (e.g. 25 mcg tablets) are classified
in N02CA.
N04BD Monoamine oxidase B inhibitors
N04BX Other dopaminergic agents
This group comprises dopaminergic agents which cannot be classified in
the preceding groups.
The combination of levodopa, decarboxylase inhibitor and COMT
inhibitor is classified in N04BA - Dopa and dopa derivatives.
N05 PSYCHOLEPTICS
The group is divided into therapeutic subgroups:
N05A - Antipsychotics
N05B - Anxiolytics
N05C - Hypnotics and sedatives
215